No Detail Found!

Novel strategy for AAV vector design in gene therapy and its biosafety assessment

Author(s)
Caihong Gao School of Life Sciences Fudan University Shanghai,Shanghai,China
Abstract
To develop a novel AAV vector design for gene therapy by synthesizing the AAVITR microcarrier sequence, constructing and identifying the amplification plasmid, and evaluating the properties of the microcarrier prepared by heat denaturation. We also assess the biosafety of this new vector by examining its toxicity, immunogenicity, and potential for immune cell infiltration. The AAVITR micro carrier sequence was designed and synthesized, followed by the construction of an amplification plasmid to express the vector sequence and the identification of pUC57-minivector. The in vitro expression of the AAVITR micro carrier was analyzed and its safety was assessed through toxicity, immunogenicity, and immune cell infiltration assays. In safety assessments, the new vector demonstrated superior survival and apoptosis rates compared to conventional vectors. Additionally, the AAV-ITR micro carrier showed significant advantages in immune cell infiltration, cytokine levels, and antibody production, indicating a potent immune response. The novel AAVITR micro vector developed in this study offers improved safety and efficacy in gene therapy, with notable advantages in immune response and biosafety, providing a promising alternative to traditional AAV vectors.
Publication Details
Page(s) 1174-1183
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 4, Year: 2025

Request the full text from PASTIC

Keywords
cytokines, Immune response, Safety assessment, AAV vector, antibody production
References
Au HKE,Isalan M,Mielcarek M M .2022 .Gene therapy advances: A meta-analysis of AAV usage in clinical settings. Front. Med, 8 : 809118.
Buck TM,Wijnholds J .2020 .Recombinant adenoassociated viral vectors (rAAV)-vector elements in ocular gene therapy clinical trials and transgene expression and bioactivity assays. Int. J. Mol. Sci, 21(12) : 4197.
Bulcha JT,Wang Y,Ma H,Tai PWL,Gao G .2021 .Viral vector platforms within the gene therapy landscape. Signal Transduct. Target. Ther., 6(1) : 53.
El Andari J,Grimm D J .2021 .Production, processing, and characterization of synthetic AAV gene therapy vectors. , 16(1) : 2000025.
Ghosh S,Brown AM,Jenkins C,Campbell K C .2020 .Viral vector systems for gene therapy: A comprehensive literature review of progress and biosafety challenges. Appl, 25(1) : 7-18.
Hacker UT,Bentler M,Kaniowska D,Morgan M,Büning H M .1889 .Towards clinical implementation of adeno-associated virus (AAV) vectors for cancer gene therapy: Current status and future perspectives. Cancers, 12(7) : .
Issa SS,Shaimardanova AA,Solovyeva VV,Rizvanov AA .2023 .Various AAV serotypes and their applications in gene therapy: An overview. Cells, 12(5) : 785.
Kishimoto TK,Samulski RJ .2022 .Addressing high dose AAV toxicity 'one and done'or 'slower and lower' ? Expert Opin. , 22(9) : 1067-1071.
Samulski RJ Li C .2020 .Engineering adenoassociated virus vectors for gene therapy. Nat. Rev. Genet, 21(4) : 255-272.
Mendell JR,Al-Zaidy SA,Rodino-Klapac LR,Goodspeed K,Gray SJ,Kay CN,Boye SL,Boye SE,George LA,Salabarria S,Corti M,Byrne BJ,Tremblay JP .2021 .Current clinical applications of in vivo gene therapy with AAVs. Mol. Ther, 29(2) : 464-488.
Nidetz NF,McGee MC,Tse LV,Li C,Cong L,Li Y,Huang W Y .2020 .Adeno-associated viral vectormediated immune responses: Understanding barriers to gene delivery. Pharmacol, 207 : 107453.
Pham Q,Glicksman J,Chatterjee A .2024 .Chemical approaches to probe and engineer AAV vectors. Nanoscale, 16(29) : 13820-13833.
Pupo A,Fernández A,Low SH,François A,SuárezAmarán L,Samulski RJ .2022 .AAV vectors: The Rubik's cube of human gene therapy. Mol. Ther, 30(12) : 3515-3541.
Ronzitti G,Gross DA,Mingozzi F DA .2020 .Human immune responses to adeno-associated virus (AAV) vectors. , 11 : 670.
Schmidt M,Foster GR,Coppens M,Thomsen H,Dolmetsch R,Heijink L,Monahan PE,Pipe SW PE .2023 .Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B. , 7(17) : 4966-4969.
Shirley JL,de Jong YP,Terhorst C,Herzog RW C .2020 .Immune responses to viral gene therapy vectors. Mol. Ther, 28(3) : 709-722.
Sidonio RF,Pipe SW,Callaghan MU,Valentino LA,Monahan PE,Croteau SE .2021 .Discussing investigational AAV gene therapy with hemophilia patients: a guide. Blood Rev., 47 : 100759.
Tran NT,Heiner C,Weber K,Weiand M,Wilmot D,Xie J,Wang D,Brown A,Manokaran S,Su Q,Zapp ML,Gao G,Tai PWL G .2020 .AAV-genome population sequencing of vectors packaging CRISPR components reveals design-influenced heterogeneity. Mol. Ther. Methods Clin. Dev, 18 : 639-651.
Wang Y,Bruggeman KF,Franks S,Gautam V,Hodgetts SI,Harvey AR,Williams RJ,Nisbet DR .2021 .Is viral vector gene delivery more effective using biomaterials? Adv. , 10(1) : 2001238.
Xu Q,Chen S,Hu Y,Huang W Y .2021 .Landscape of immune microenvironment under immune cell infiltration pattern in breast cancer. Front. Immunol., 12 : 711433.
Zhao H,Lee KJ,Daris M,Lin Y,Wolfe T,Sheng J,Plewa C,Wang S,Meisen WH .2020 .Creation of a highyield AAV vector production platform in suspension cells using a design-of-experiment approach. Mol. Ther. Methods Clin. Dev, 18 : 312-320.
Zhao Z,Anselmo AC,Mitragotri S AC .2022 .Viral vector-based gene therapies in the clinic. Bioeng. Transl. Med, 7(1) : e10258.
Zu H,Gao D H .2021 .Non-viral vectors in gene therapy: Recent development, challenges and prospects. , 23(4) : 78.
0

Citations

0

Downloads

55

Views